

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
33687-US-PCT  
APPLICATION NO.APPLICANT  
FELDMAN ET AL.  
FILING DATE

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA	2003/0114389A1	6/19/03	Webb	514	19	
AB	2003/229007	12/11/03	Levi et al.	514	2	
AC	4,885,292	12/5/89	Ryono et al.	514	211	
AD	5,376,638	12/27/94	Young et al.	514	12	
AE	5,182,266	1/26/93	Kleinert	514	18	
AF	5,202,322	4/13/93	Allen et al.	514	228.2	
AG	5,821,232	10/13/98	Fossa	514	18	
AH						

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO
AI 0 518 676 A2	12/16/92	EP			<input type="checkbox"/> <input type="checkbox"/>
AJ 0 573 652 A1	9/17/92	EP			<input type="checkbox"/> <input type="checkbox"/>
AK EP 1 312 379 A1	5/21/03	EP			<input type="checkbox"/> <input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AL	Allikmets, "Aliskiren Speedel" Current Opinion in Investigational Drugs, Vol. 3, No. 10, pp 1479-1482, (2002)
AM	Azizi et al. "Pharmacologic Demonstration of the Synergistic Effects of combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II-Renin Feedback Interruption." J. Am. Soc. Nephrol 15: pp. 3126-3133 (2004).
AN	Beers et al., The Merck Manual of diagnosis and Therapy, Seventeenth Edition XP002364176 (1999)
AO	Boger et al., "Dose-dependent effects on blood pressure and the rennin-angiotensin system with a new orally active rennin inhibitor." Clinical Pharmacology and Therapeutics, vol. 53, no. 2, p 140 (1993)
AP	Fossa et al., "Synergistic Effect on Reduction in Blood Pressure With coadministration of a Renin Inhibitor or an Angiotensin-Converting Enzyme Inhibitor With an Angiotensin II Receptor Antagonist" Drug Development Research 33: pp 422-428 (1994)
AQ	Himmelmann et al., "Remikiren (Ro 42-5892) - An Orally Active Renin Inhibitor in Essential Hypertension" AJH, Vol. 9, No. 6, pp 517-522 (1996)
AR	Maibaum et al. "Renin inhibitors as novel treatments for cardiovascular disease" Monthly Focus: Cardiovascular, Renal, Endocrine & Metabolic, Expert Opinion. Ther. Patents No. 13(5), pp 589-603 (2003)

EXAMINER

DATE CONSIDERED

\*EXAMINER:

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 2 of 2

ATTY. DOCKET NO.  
33687-US-PCT  
APPLICATION NO.APPLICANT  
FELDMAN ET AL.  
FILING DATE

Group

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BA	WO 01/15673 A2	3/8/01	WO				
	BB	WO 01/15674 A	3/8/01	WO				
	BC	WO 03/035046A2	5/1/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BD	WO 03/097098A1	11/27/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BE	WO 03/099279A1	12/4/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BF	WO 03/099767A1	12/4/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BG	WO 92/10097	6/25/92	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BH	WO2004/002549A1	1/8/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BI	WO2004/002957A1	1/8/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BJ	WO2004/100871A2	11/25/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BK	WO 02/40007 A1	5/23/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BL	WO2005/023183A2	3/17/05	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BM	WO2005/054244A2	6/16/05	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BN	WO2005/070406	8/4/05	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BO	WO2005/077418A1	8/25/05	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>
	BR						<input type="checkbox"/>	<input type="checkbox"/>
	BS						<input type="checkbox"/>	<input type="checkbox"/>
	BT						<input type="checkbox"/>	<input type="checkbox"/>
	BU						<input type="checkbox"/>	<input type="checkbox"/>
	BV						<input type="checkbox"/>	<input type="checkbox"/>
	BW						<input type="checkbox"/>	<input type="checkbox"/>
	BX						<input type="checkbox"/>	<input type="checkbox"/>
	BY						<input type="checkbox"/>	<input type="checkbox"/>
	BZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609; Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.